Adnexal masses in patients with colorectal cancer

Akgör, Utku; Kuru, Oğuzhan; Soyak, Burcu; Güneş, Ali Can; Uyanık, Esra; Gültekin, Murat; Özgül, Nejat; Salman, Coskun

doi:10.1016/j.jogoh.2020.101898

Cited by 2 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that the ovary appears to be a ‘sanctuary’ for tumor cells, providing a favorable microenvironment for tumor growth, and that metastatic ovarian tumors do not respond well to chemotherapy. Therefore, surgery appears to be the only viable alternative ( 57 , 59 ). In this case, we found involvement of the right ovary during the initial radical surgery for rectal cancer, and performed resection of the metastases at the same time, and then found metastases in the left ovary 2 years later and promptly resected them.…”

Section: Discussionmentioning

confidence: 99%

“…Utku Akgor et al. argue that: Microscopic metastases can occur even in normal-appearing ovaries, and bilateral salpingo-oophorectomy should be the standard of care for all patients with ovarian metastases from CRC ( 59 , 63 ).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, CRC may also increase the risk of ovarian metastases by spreading through the peritoneum (62). Utku Akgor et al argue that: Microscopic metastases can occur even in normal-appearing ovaries, and bilateral salpingo-oophorectomy should be the standard of care for all patients with ovarian metastases from CRC (59,63).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries

et al. 2023

View full text Add to dashboard Cite

BackgroundRectal cancer has a high risk of recurrence and metastasis, with median survival ranging from 24 months to 36 months. K-RAS mutation is a predictor of poor prognosis in rectal cancer. Advanced rectal cancer can be stopped in its tracks by pelvic exenteration.Case summaryA 51-year-old woman was diagnosed with advanced rectal cancer (pT4bN2aM1b, stage IV) with the KRAS G12D mutation due to a change in bowel habits. The patient had experienced repeated recurrences of rectal cancer after initial radical resection, and the tumor had invaded the ovaries, sacrum, bladder, vagina and anus. Since the onset of the disease, the patient had undergone a total of seven surgeries and long-term FOLFIRI- or XELOX-based chemotherapy regimens, with the targeted agents bevacizumab and regorafenib. Fortunately, the patient was able to achieve intraoperative R0 resection in almost all surgical procedures and achieve tumor-free survival after pelvic exenteration. The patient has been alive for 86 months since her diagnosis.ConclusionsPatients with advanced rectal cancer can achieve long-term survival through active multidisciplinary management and R0 surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%